Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 14, 2020•Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilationGENEVA and RADNOR, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. announced today that NeuroRx has completed final...
-
March 26, 2020Aviptadil is a patented synthetic form of Vasoactive Intestinal Polypeptide that has previously shown promise in treating ARDS
RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation. have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of...
-
March 25, 2020NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics' (RLF)
WILMINGTON, DE and RADNOR, PA March 25, 2020 / NeuroRx, a clinical stage biopharma company focused on development of CNS drugs, today announced an expansion of scope to include the co-development...
-
February 10, 2020
NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am. The company's CEO, Dr. Jonathan Javitt will be presenting an overview of recent results...
-
January 8, 2020Company to attend upcoming JP Morgan Healthcare Conference
NeuroRx, Inc announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need...
Click here to view our corporate presentation or on the image below
 |
